Cochrane Database Syst Rev (2): CD006586. doi:10.1002/14651858.CD006586.pub4. PMID 22336820. Machado RB, Pompei Lde M, Giribela AG, Giribela CG (January 2011). "Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits". Womens Health. 7 (1): 19–30. doi:10.2217/whe.10.84. PMID 21175386. Mallareddy M, Hanes V, White WB (2007). "Drospirenone, a new progestogen, for postmenopausal women with hypertension". Drugs Aging. 24 (6): 453–66. doi:10.2165/00002512-200724060-00002. PMID 17571911. S2CID 39236155. Motivala A, Pitt B (2007). "Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens?". Drugs. 67 (5): 647–55. doi:10.2165/00003495-200767050-00001. PMID 17385938. S2CID 22985078. Oelkers W (December 2002). "Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone". Eur J Contracept Reprod Health Care. 7 Suppl 3: 19–26, discussion 42–3. PMID 12659403. Oelkers W (December 2000). "Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone". Eur J Contracept Reprod Health Care. 5 Suppl 3: 17–24. PMID 11246598. Oelkers W (March 2004). "Drospirenone, a progestogen with antimineralocorticoid properties: a short review". Mol. Cell. Endocrinol. 217 (1–2): 255–61. doi:10.1016/j.mce.2003.10.030. PMID 15134826. S2CID 19936032. Oelkers W (February 2002). "The renin-aldosterone system and drospirenone". Gynecol. Endocrinol. 16 (1): 83–7. doi:10.1080/gye.16.1.83.87. PMID 11915587. S2CID 32410408. Oelkers WH (October 2005). "Drospirenone in combination with estrogens: for contraception and hormone replacement therapy". Climacteric. 8 Suppl 3: 19–27. doi:10.1080/13697130500330341. PMID 16203652. S2CID 42837148. Palacios S, Foidart JM, Genazzani AR (November 2006). "Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism" (PDF). Maturitas. 55 (4): 297–307. doi:10.1016/j.maturitas.2006.07.009. hdl:2268/9932. PMID 16949774. Pérez-López FR (June 2008).
Two processes that occur during the embryonic development of the paramesonephric ducts — fusion and reabsorption — can be affected to different degrees.There is also a hybrid bicornuate uterus: External fundal depressions of variable depths associated with a septate uterus can be seen by laparoscopy, indicating the coexistence of the two anomalies. These cases are candidates for hysteroscopic metroplasty under appropriate sonographic and/or laparoscopic monitoring.An obstructed bicornuate uterus showing uni or bilateral obstruction might also be possible. The unilateral obstruction is more difficult to diagnose than the bilateral obstructive. A delay in the diagnosis can be problematic and compromise the reproductive abilities of those cases. Treatment
Bicornuate uterus typically requires no treatment. In those who do need treatment, metroplasty is the surgical correction of choice. Women who have recurrent miscarriage with no other explanation may benefit from surgery. Epidemiology
The occurrence of all types of paramesonephric duct abnormalities in women is estimated around 0.4%. A bicornuate uterus is estimated to occur in 0.1–0.6% of women in the US. It is possible that this figure is an underestimate, since subtle abnormalities often go undetected. Some intersex individuals whose external genitalia are perceived as being male may nonetheless have a variably shaped uterus. Women exposed in utero to diethylstilbestrol (DES) are at risk for this abnormality. In pregnancy
A bicornuate uterus is an indication for increased surveillance of a pregnancy, though most women with a bicornuate uterus are able to have healthy pregnancies.